Interní Med. 2016; 18(2): 71-73 | DOI: 10.36290/int.2016.017
Do we use statins enough? News in the combination treatment by statins ánd ezetimibe
- Centrum preventivní kardiologie, II. interní klinika LF a FN v Plzni, UK v Praze
Many patients do not reach target cholesterol levels because of the underdosed statin treatment. The IMPROVE-IT study shows
that a further lowering of the LDL cholesterol in patients on statins after an acute coronary syndrome by ezetimibe leads to
a further cardiovascular risk reduction.
Keywords: LDL cholesterol, statin, ezetimibe
Published: May 1, 2016 Show citation
References
- Mayer O jr, et al. The changes in cardiovascular prevention practice between 1995 and 2012 in the Czech Republic. A comparison of EUROASPIRE I, II, III and IV study. Cor et Vasa 2014; 56: e91-e97.
Go to original source... - Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials, Lancet 2010; 376: 1670-1681. Go to original source...
- Reiner Z, Catapano A, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS), European Heart Journal 2011; 32: 1769-1818.
- Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and ravastatin Gross doses (STELLAR Trial). Am J Cardiol 2003; 92: 152-160. Go to original source...
Go to PubMed... - Newman C, Tsai J, Szarek M, et al. Comparative Safety of Atorvastatin 80 mg Versus 10 mg. Am J Cardiol 2006; 7: 61-67. Go to original source... Go to PubMed...
- Sattar N, Taskinen MR. Statins are diabetogenic-myth or reality?, Atherosclerosis. Supplements 2012; 13: 1-10. Go to original source... Go to PubMed...
- Carter AA, Gomes T, Camacho X, et al. Risk of incident diabetes among patients treated with statins: population based study, British Medical Journal 2013; 346: f2610. Go to original source... Go to PubMed...
- Pearson TA, Denke MA, McBride PE, et al. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc 2005; 80: 587-595. Go to original source...
- Kastelein JJ, Sager PT, de Groot E, et al. Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. Am Heart J 2005149: 234-239. Go to original source... Go to PubMed...
- SHARP Collaborative Group, Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease, American Heart Journal 2010; 160: 785-794. Go to original source... Go to PubMed...
- Rossebo AB, Pedersen TR, Boman K, et al. for the SEAS Investigators, Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis, New England Journal of Medicine 2008; 359: 1343-1356. Go to original source...
- Califf RM, Lokhnygina Y, Cannon PC, et al. An update on the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design, American Heart Journal 2010; 159: 705-709. Go to original source... Go to PubMed...